Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Volume 2 (2005), Issue 9 (September)

1. Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis.
   Genes Immun, 6(6): 467-71. [Abstract] [Full-text]
2. FcgammaRIIa is a target for modulation by TNFalpha in human neutrophils.
   Clin Immunol, 117(1): 78-86. [Abstract] [Full-text]
3. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis.
   Nat Med, 11(9): 936-43. [Abstract] [Full-text]
4. Transoral resection of odontoid process fragment in a rheumatoid patient using Coblation electrosurgery.
   Br J Neurosurg, 19(1): 77-8. [Abstract] [Full-text]
5. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
   Arthritis Rheum, 52(9): 2616-24. [Abstract] [Full-text]
6. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.
   Arthritis Rheum, 52(9): 2693-6. [Abstract] [Full-text]
7. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
   Arthritis Rheum, 52(9): 2686-92. [Abstract] [Full-text]
8. Dehydroascorbate transport in human chondrocytes is regulated by hypoxia and is a physiologically relevant source of ascorbic acid in the joint.
   Arthritis Rheum, 52(9): 2676-85. [Abstract] [Full-text]
9. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
   Arthritis Rheum, 52(9): 2751-60. [Abstract] [Full-text]
10. Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages.
    Arthritis Rheum, 52(9): 2666-75. [Abstract] [Full-text]
11. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
    Arthritis Rheum, 52(9): 2740-50. [Abstract] [Full-text]
12. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3.
    Arthritis Rheum, 52(9): 2656-65. [Abstract] [Full-text]
13. Antigen microarray profiling of autoantibodies in rheumatoid arthritis.
    Arthritis Rheum, 52(9): 2645-55. [Abstract] [Full-text]
14. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility.
    Arthritis Rheum, 52(9): 2637-44. [Abstract] [Full-text]
15. Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score.
    Arthritis Rheum, 52(9): 2865-72. [Abstract] [Full-text]
16. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states.
    Arthritis Rheum, 52(9): 2625-36. [Abstract] [Full-text]
17. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis.
    J Immunol Methods, 304(1): 126-36. [Abstract] [Full-text]
18. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis?
    Ann Rheum Dis, 64(10): 1443-50. [Abstract] [Full-text]
19. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    N Engl J Med, 353(11): 1114-23. [Abstract] [Full-text]
20. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    J Med Chem, 48(19): 5966-79. [Abstract] [Full-text]
21. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
    Ann Rheum Dis, 64(10): 1410-3. [Abstract] [Full-text]
22. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study.
    Ann Rheum Dis, 64(10): 1451-5. [Abstract] [Full-text]
23. Performance of health status measures with a pen based personal digital assistant.
    Ann Rheum Dis, 64(10): 1480-4. [Abstract] [Full-text]
24. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
    Ann Rheum Dis, 64(10): 1414-20. [Abstract] [Full-text]
25. Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration.
    Ann Rheum Dis, 64(10): 1397-405. [Abstract] [Full-text]
26. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.
    Ann Rheum Dis, 64(10): 1421-6. [Abstract] [Full-text]
27. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome.
    Ann Rheum Dis, 64(10): 1474-9. [Abstract] [Full-text]
28. Prevalence of rheumatoid arthritis in France: 2001.
    Ann Rheum Dis, 64(10): 1427-30. [Abstract] [Full-text]
29. Direct costs related to rheumatoid arthritis: the patient perspective.
    Ann Rheum Dis, 64(10): 1456-61. [Abstract] [Full-text]
30. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis.
    Ann Rheum Dis, 64(10): 1510-2. [Abstract] [Full-text]
31. Impact of pregnancy on health related quality of life evaluated prospectively in pregnant women with rheumatic diseases by the SF-36 health survey.
    Ann Rheum Dis, 64(10): 1494-9. [Abstract] [Full-text]
32. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab.
    Ann Rheum Dis, 64(10): 1462-6. [Abstract] [Full-text]
33. Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells.
    Ann Rheum Dis, 64(10): 1436-42. [Abstract] [Full-text]
34. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment.
    Ann Rheum Dis, 64(10): 1503-6. [Abstract] [Full-text]
35. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Rheumatology (Oxford), 44(10): 1277-81. [Abstract] [Full-text]
36. Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis.
    Rheumatology (Oxford), 44(10): 1299-302. [Abstract] [Full-text]
37. Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
    Rheumatology (Oxford), 44(10): 1255-62. [Abstract] [Full-text]
38. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population.
    Rheumatology (Oxford), 44(10): 1263-6. [Abstract] [Full-text]
39. The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project).
    Rheumatology (Oxford), 44(10): 1294-8. [Abstract] [Full-text]
40. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis.
    Am J Hum Genet, 77(4): 567-81. [Abstract] [Full-text]
41. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.
    Proc Natl Acad Sci U S A, 102(38): 13562-7. [Abstract] [Full-text]
42. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis.
    Scand J Immunol, 62(3): 312-7. [Abstract] [Full-text]
43. Molecular study of WISP3 in nine families originating from the Middle-East and presenting with progressive pseudorheumatoid dysplasia: identification of two novel mutations, and description of a founder effect.
    Am J Med Genet A, 138(2): 118-26. [Abstract] [Full-text]
44. Work ability of Dutch employees with rheumatoid arthritis.
    Scand J Rheumatol, 34(4): 277-83. [Abstract] [Full-text]
45. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
    Scand J Rheumatol, 34(4): 269-76. [Abstract] [Full-text]
46. Tibio-talocalcaneal arthrodesis as a primary procedure using a retrograde intramedullary nail: a retrospective study of 26 patients with rheumatoid arthritis.
    Acta Orthop, 76(4): 580-7. [Abstract] [Full-text]
47. Radiostereometric analysis of the double-coated STAR total ankle prosthesis: a 3-5 year follow-up of 5 cases with rheumatoid arthritis and 5 cases with osteoarthrosis.
    Acta Orthop, 76(4): 573-9. [Abstract] [Full-text]

© 2004-2008 Rheumatoid Arthritis Research Today. All Rights Reserved.